The 2023-2024 Virus Season: Parents Struggle to Access New RSV Drug
The 2023-2024 virus season is the first since the FDA approved a new preventative drug for respiratory syncytial virus (RSV) in infants and toddlers. Although this breakthrough has brought relief to parents, issues such as high demand, supply shortages, and insurance confusion have made it difficult for many to obtain the drug.
What You Should Know About the New RSV Drug
The FDA-approved drug, known as Nirsevimab or Beyfortus, is recommended by the CDC for babies born during or entering their first RSV season, as well as children between 8 and 19 months old who are vulnerable to severe RSV disease. Nirsevimab is administered via shot and acts as a preventative drug rather than a vaccine. It delivers long-acting antibodies to provide passive immunity and prevent the spread of RSV, which can cause bronchiolitis and lead to hospitalization in infants.
The Struggles of Parents Trying to Obtain the Drug
Due to the risks associated with RSV, parents are eager to obtain the drug, but it’s facing supply shortages. Sanofi, one of the drug manufacturers, has reported a higher demand than anticipated, leaving many eligible infants unprotected. To address this, the CDC has recommended prioritizing the highest-risk babies and reserving the limited supply of Nirsevimab for them. However, even parents of top-priority babies have reported difficulties in booking appointments and finding the drug available.
Two Moms Share Their Experiences
1. Arlie’s Experience
Arlie, based in North Carolina, is eager to get the RSV drug for her 6-month-old baby. However, since her baby is near the age cutoff recommended by the CDC, there has been uncertainty about when he can receive the shot. Arlie hopes that the issues surrounding insurance and supply will be resolved before her baby’s next visit in early November. In the meantime, her family is taking extra precautions to keep the baby safe.
2. Leslie’s Experience
Leslie, a mom of three boys in Austin, Texas, proactively asked her pediatrician about the RSV drug to protect her youngest son. However, the doctor’s office informed her that insurance coverage was uncertain due to the drug being new on the market. As a result, Leslie and her family decided to pay the full cost out of pocket. Although they hope for eventual reimbursement, they worry that the upfront cost and logistical challenges may deter other families from accessing the drug.
While the new RSV drug brings hope to parents, supply shortages and insurance issues pose significant challenges. As parents continue to navigate these obstacles, it’s crucial to prioritize the health and safety of infants and toddlers during the virus season.
